Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Follicular 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Rituximab 17Cyclophosphamide 8zanubrutinib 7Bendamustine Hydrochloride 7obinutuzumab 6Lenalidomide 6venetoclax 5blinatumomab 5acalabrutinib 5Vincristine 5fludarabine 4Prednisone 4Methotrexate 4Doxorubicin 4Cytarabine 4Brentuximab Vedotin 4ibrutinib 3Specimen Handling 3Dexamethasone 3Crizotinib 3tisagenlecleucel 2tafasitamab 2polatuzumab vedotin 2pirtobrutinib 2pegaspargase 2idelalisib 2duvelisib 2axicabtagene ciloleucel 2avapritinib 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × duvelisib × Lymphoid × Clear all
NCT02204982 2023-09-28

DYNAMO + R

SecuraBio

Phase 3 Terminated
13 enrolled 10 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Hereditary Sensory and Autonomic Neuropathies

NCT02004522 2023-09-21

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

SecuraBio

Phase 3 Completed
319 enrolled 18 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡